Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome

Leukemia

Volumn 22, Issue 12, 2008, Pages 2230-2239

  Krejsgaard, T ^a   Gjerdrum, L M ^b   Ralfkiaer, E ^b   Lauenborg, B ^a   Eriksen, K W ^a   Mathiesen, A M ^a   Bovin, L F ^c   Gniadecki, R ^a   Geisler, C ^a   Ryder, L P ^a   Zhang, Q ^d   Wasik, M A ^d   Odum N ^a   Woetmann, A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; JANUS KINASE 3; PROTEIN ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CELL GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REPORTER GENE; SEZARY SYNDROME; WESTERN BLOTTING; WILD TYPE;

EID: 57849154832     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.224     Document Type: Article

References (47)

1. Berger CL, Mariwalla K, Girardi M, Edelson RL. Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma. Adv Dermatol 2004; 20: 217-235.
2. Dummer R. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). Semin Oncol 2006; 33: S33-S36.
3. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
4. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM et al Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798-812.
5. Bagot M, Boumsell L, Bensussan A. Immunopathogenesis of cutaneous T-cell lymphomas. Hematol Oncol Clin North Am 2003; 17: 1313-1317, vii.
6. Bagot M, Nikolova M, Schirm-Chabanette F, Wechsler J, Boumsell L, Bensussan A. Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann N Y Acad Sci 2001; 941: 31-38.
7. Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JM. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol 1999; 6: 79-84.
8. Vowels BR, Lessin SR, Cassin M, Jaworsky C, Benoit B, Wolfe JT et al Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669-673.
9. Linnemann T, Tumenjargal S, Gellrich S, Wiesmuller K, Kaltoft K, Sterry W et al. Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur J Immunol 2001; 31: 156-165.
10. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006; 20: 1759-1766.
11. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC et al Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996; 93: 9148-9153.
12. Nielsen M, Kaltoft K, Nordahl M, Ropke C, Geisler C, Mustelin T et al Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci USA 1997; 94: 6764-6769.
13. Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M et al STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001; 97: 1056-1062.
14. Krishnadasan R, Bifulco C, Kim J, Rodov S, Zieske AW, Vanasse GJ. Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma. Br J Haematol 2006; 135: 72-75.
15. Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. JAMA 1992; 267: 1354-1358.
16. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N et al Cutaneous T-cell lymphoma: Malignant proliferation of T-regulatory cells. Blood 2005; 105: 1640-1647.
17. Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123-1129.
18. Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126 2217-2223.
19. Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21 2512-2518.
20. Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 2007; 7: 305-310.
21. Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC et al The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 2005; 115: 3276-3284.
22. Smith EL, Finney HM, Nesbitt AM, Ramsdell F, Robinson MK. Splice variants of human FOXP3 are functional inhibitors of human CD4+ T-cell activation. Immunology 2006; 119: 203-211.
23. Lopes JE, Torgerson TR, Schubert LA, Anover SD, Ocheltree EL, Ochs HD et al. Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor. J Immunol 2006; 177 3133-3142.
24. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA 2005; 102: 5138-5143.
25. Du J, Huang C, Zhou B, Ziegler SF. Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J Immunol 2008; 180: 4785-4792.
26. Kaltoft K, Bisballe S, Rasmussen HF, Thestrup-Pedersen K, Thomsen K, Sterry W. A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 1987; 279: 293-298.
27. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 2000; 157: 1137-1146.
28. Kaltoft K, Bisballe S, Dyrberg T, Boel E, Rasmussen PB, ThestrupPedersen K. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 1992; 28A: 161-167.
29. Kaltoft K, Hansen BH, Pedersen CB, Pedersen S, ThestrupPedersen K. Common clonal chromosome aberrations in cytokinedependent continuous human T-lymphocyte cell lines. Cancer Genet Cytogenet 1995; 85 68-71.
30. Kaltoft K, Hansen BH, Thestrup-Pedersen K. Cytogenetic findings in cell lines from cutaneous T-cell lymphoma. Dermatol Clin 1994; 12 295-304.
31. Geisler C, Scholler J, Wahi MA, Rubin B, Weiss A. Association of the human CD3-zeta chain with the alpha beta-T cell receptor/CD3 complex. Clues from a T cell variant with a mutated T cell receptor-alpha chain. J Immunol 1990; 145: 1761-1767.
32. Siegel JP, Mostowski HS. A bioassay for the measurement of human interleukin-4. J Immunol Methods 1990; 132: 287-295.
33. Von Willebrand M, Jascur T, Bonnefoy-Berard N, Yano H, Altman A, Matsuda Y et al. Inhibition of phosphatidylinositol 3-kinase blocks T cell antigen receptor/CD3-induced activation of the mitogen-activated kinase Erk2. Eur J Biochem 1996; 235: 828-835.
34. Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004; 18: 1288-1295.
35. Woetmann A, Lovato P, Eriksen KW, Krejsgaard T, Labuda T, Zhang Q et al. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 2007; 109: 3325-3332.
36. Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood 2006; 108: 1058-1064.
37. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C et al. Constitutive STAT3-activation in Sezary syndrome: Tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 2001; 15: 787-793.
38. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007; 109: 4368-4375.
39. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
40. Echchakir H, Bagot M, Dorothee G, Martinvalet D, Le Gouvello S, Boumsell L et al. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 2000; 115: 74-80.
41. Saed G, Fivenson DP, Naidu Y, Nickoloff BJ. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. J Invest Dermatol 1994; 103: 29-33.
42. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
43. Kubach J, Lutter P, Bopp T, Stoll S, Becker C, Huter E et al. Human CD4+CD25+ regulatory T cells: Proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 2007; 110: 1550-1558.
44. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA 2004; 101: 10398-10403.
45. Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, Courtois G et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006; 107: 2354-2363.
46. Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, Fukazawa T et al. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation. Bioorg Med Chem 2003; 11 383-391.
47. Choi BM, Pae HO, Jeong YR, Kim YM, Chung HT. Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem Biophys Res Commun 2005; 327: 1066-1071.